NAD+ for Long-COVID Brain Fog: What's the Evidence?

If you're dealing with the cognitive fog that can linger after COVID-19, you've probably seen NAD+ — as a supplement, an IV drip, or a nasal spray — pitched as a fix. The pitch has real mechanistic appeal, and unlike most NAD+/brain-fog claims, this one has finally been put to a direct randomized test. The honest summary up front: NAD+ replenishment is a biologically reasonable idea for long COVID, but the first randomized controlled trial that tested it raised NAD+ levels and did not significantly improve cognition, fatigue, sleep, or mood. That is the most important sentence on this page, and it's worth understanding why the idea was plausible — and why a plausible idea still needs a trial.

First, what "long-COVID brain fog" actually is

"Long COVID" — formally post-COVID-19 condition — is generally defined as symptoms that persist roughly three months after a SARS-CoV-2 infection, last at least two months, and aren't explained by another diagnosis¹. Cognitive dysfunction — the slowed thinking, word-finding trouble, and poor concentration people call "brain fog" — is one of its hallmark features alongside fatigue¹.

It is not a vague or imagined symptom. A large community study published in the New England Journal of Medicine measured cognitive deficits after COVID-19 that scaled with severity — on the order of a few IQ points in those who recovered quickly, larger in people with persistent long-COVID symptoms². So the target is real and measurable. The open question is whether raising NAD+ does anything about it.

Why NAD+ became a candidate

NAD+ is a coenzyme at the center of how cells turn fuel into energy. The reason researchers took it seriously for long COVID specifically — rather than as one more generic "energy" supplement — is that long-COVID biology points toward a cellular energy-production problem.

Multiple lines of evidence describe mitochondrial dysfunction in post-acute SARS-CoV-2 infection, and reviews have proposed that disruption of the NAD+ metabolome is part of that picture, plausibly contributing to the persistent fatigue and metabolic abnormalities seen in patients³. Separately, the cognitive component of brain fog has been framed as a neuroinflammation phenomenon — microglial activation and inflammatory cytokines disrupting normal cognition⁴. NAD+ sits upstream of both energy metabolism and several stress-response pathways, so "top up NAD+, support struggling cells" is a coherent hypothesis.

A coherent hypothesis is exactly that, though — a reason to run a trial, not a result. NAD+ products routinely cite this kind of mechanism as if it were proof. It isn't. So what happened when someone actually tested it?

The trial that tested it directly

In 2025, EClinicalMedicine published the first randomized, placebo-controlled trial of an NAD+ precursor for long COVID. Researchers gave nicotinamide riboside (NR) at 2,000 mg/day to community-dwelling adults with long COVID, over roughly 20 weeks, with a placebo-controlled comparison⁵.

The supplement did what NAD+ precursors reliably do: NR raised blood NAD+ levels 2.6- to 3.1-fold. The pharmacology worked. But on the outcomes people actually care about, there were no significant differences versus placebo — not in cognition (across multiple cognitive measures), not in fatigue, not in sleep quality, and not in anxiety or depression symptoms⁵. The number in the blood moved; the symptoms did not.

This is the single most relevant data point for anyone considering NAD+ for long-COVID fog, because it tests the exact claim — an NAD+ precursor, in long-COVID patients, measuring cognition and fatigue — rather than extrapolating from aging or other conditions.

What the "early promise" headlines were actually about

You may have seen coverage describing the same trial as showing "early promise." That framing comes from the study's exploratory, within-group analyses, which hinted at improvements in executive function, fatigue, sleep, and mood after about 10 weeks of NR⁵. It's worth being precise about what that means.

A within-group, exploratory signal is hypothesis-generating, not confirmatory. People in trials — including those on placebo — often improve over months for reasons unrelated to the pill: natural recovery, regression to the mean, and the placebo effect itself. The whole point of the placebo-controlled, between-group comparison is to subtract those out, and once you do, the NR-versus-placebo difference wasn't significant⁵. So the honest read is: the controlled comparison was null, the exploratory hints justify a larger trial, and neither one is evidence that NAD+ reliably lifts long-COVID brain fog today.

This fits the broader NAD+/cognition pattern

The long-COVID result isn't an outlier — it matches what NAD+ research keeps showing across conditions. Precursors raise the biomarker reliably (an oral NMN formulation increased circulating NAD+ and its metabolome in older adults⁶), but the cognitive payoff keeps failing to appear. The cleanest example outside long COVID: a randomized trial of NR in older adults with mild cognitive impairment raised NAD+ but did not improve cognition versus placebo⁷.

The one frequently-cited "positive" cognition trial — in Alzheimer's patients — used a multi-ingredient cocktail (NR combined with L-serine, N-acetylcysteine, and L-carnitine tartrate), so any benefit can't be pinned on NAD+/NR alone and doesn't transfer to long-COVID fog⁸. Across the board, raising NAD+ is the easy part to prove; changing how a person thinks and feels is the part that keeps not happening. For the full version of this pattern, see our pillar guide, Does NAD+ Help Brain Fog?, and the deeper review, NAD+, Brain Fog & Focus: What the Evidence Shows.

What about IV or nasal NAD+ for long COVID?

Long-COVID clinics often market IV NAD+ drips, and you'll find nasal NAD+ sprays sold "for the brain." For long COVID specifically, the efficacy evidence here is even thinner than for oral precursors — essentially nonexistent. The only human parenteral-NAD+ data is a small pilot that simply tracked how NAD+ and its metabolites moved through plasma and urine during a 6-hour IV infusion, with no cognitive or fatigue outcomes measured at all⁹. Nasal NAD+ for cognition is unstudied in any rigorous trial. So a drip or spray sold "for long-COVID brain fog" is making a claim no trial has tested — we unpack the route question in Nasal NAD+ for Focus: Is There Evidence?.

On safety, the more reassuring data is again for oral precursors: a randomized high-dose NR trial found it generally safe and well tolerated¹⁰. But "well tolerated" is not "it worked," and oral-NR safety says nothing about injectable or nasal NAD+.

So should you try NAD+ for long-COVID brain fog?

Here's the honest framing. NAD+ for long COVID is mechanistically plausible and not proven — and unusually, we now have a direct trial showing the biomarker can move without the symptoms following⁵. That doesn't make NAD+ useless forever; larger trials may yet find a subgroup or a regimen that helps. It does mean that, today, no one can promise you a cognitive or fatigue benefit, and you should be skeptical of any product that does.

More importantly, long COVID is a medical condition, not a supplement gap. The highest-value moves are clinical:

• •Work with a clinician — ideally a long-COVID or post-COVID program — to assess and manage your specific symptom pattern.
• •Rule in the treatable contributors that also drive ordinary brain fog and frequently coexist with long COVID: poor or insufficient sleep, thyroid dysfunction, iron deficiency or anemia, and depression or anxiety. Each is testable and treatable, and addressing them does far more than any NAD+ product. We walk through the full list in What Actually Causes Brain Fog?.
• •Respect post-exertional symptoms. Many people with long COVID worsen after pushing through fatigue; pacing is a recognized part of management, not a sign of weakness.

If, after all that, you still want to try an NAD+ precursor, treat it as a low-confidence experiment layered on top of real care — not the centerpiece — and judge it by how you feel, not by a NAD+ blood number that's almost guaranteed to rise regardless. For an evidence-tiered look at the broader brain-fog supplement shelf, see the best supplements for brain fog, rated by evidence, and for the post-viral fatigue angle specifically, NAD+ for Cognitive Energy & Fatigue — where the same long-COVID NR trial found NAD+ rose but fatigue didn't budge. And if you're weighing cognitive-energy products against this evidence bar rather than the marketing, our best cognitive-energy picks rank providers honestly.